Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued a warning letter to Guoyuan Securities Co., Ltd., and its personnel Yang Shaojie and Liu Minhao for failing to exercise sufficient professional diligence in their advisory role for Anhui Fuhuang Steel Structure Co., Ltd.'s asset acquisition project, leading to inaccuracies in the independent financial advisory report [1][5]. Group 1: Regulatory Violations - Guoyuan Securities did not adequately verify the revenue recognition issues of the target company, Hefei Zhongke Junda Vision Technology Co., Ltd., resulting in a report with false records [1][5]. - The actions of Guoyuan Securities and its personnel violated multiple regulations, including Article 3 and Article 21 of the "Management Measures for Financial Advisory Services for Mergers and Acquisitions of Listed Companies" and Article 6 of the "Management Measures for Major Asset Restructuring of Listed Companies" [1][5]. Group 2: Administrative Measures - The Anhui Securities Regulatory Bureau decided to issue a warning letter as an administrative regulatory measure, which will be recorded in the integrity archives of the securities and futures market [1][5]. - The involved parties are required to enhance their understanding of relevant laws and regulations and strengthen their compliance awareness [1][5].

中国经济网北京9月10日讯 广东证监局9月8日发布关于对粤开证券股份有限公司、杨灿熙、张钦 洽采取出具警示函措施的决定（〔2025〕79号）。经查，粤开证券股份有限公司（简称"粤开证券"， 830899）作为2021年度广东太安堂药业股份有限公司重大资产出售项目的财务顾问，在接受委托出具 财务顾问专业意见过程中对标的公司收入与利润的异常情况关注不足，对其他证券服务机构出具的财务 报表审计意见和评估定价依据在引用前未履行必要的审慎核查程序。 上述执业行为不符合《上市公司并购重组财务顾问业务管理办法》（证监会令第54号）第三条、 第二十一条第一款、第二十二条第一款和《上市公司重大资产重组管理办法》（证监会令第166号）第 六条第一款、第十七条第四款的规定。杨灿熙、张钦洽作为项目主办人对上述违规行为负有主要责任。 根据《上市公司并购重组财务顾问办法》第三十九条和《上市公司重大资产重组管理办法》第五十 八条第一款的规定，广东证监局决定对粤开证券、杨灿熙、张钦洽采取出具警示函的行政监管措施。 天眼查工商信息显示，广东太安堂药业股份有限公司(曾用名：广东皮宝制药股份有限公司) ，成立 于2000年，位于广东省汕头市，是一 ...